Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
15 févr. 2023 16h30 HE
|
Ocugen
MALVERN, Pa., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Appoints Quan A. Vu as Chief Business Officer
01 févr. 2023 08h00 HE
|
Ocugen
MALVERN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
31 janv. 2023 08h00 HE
|
Ocugen
MALVERN, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
09 janv. 2023 06h00 HE
|
Ocugen
Study met both co-primary endpoints with robust immune responses COVAXIN™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the...
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
16 déc. 2022 06h30 HE
|
Ocugen
MALVERN, Pa., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis
15 déc. 2022 17h15 HE
|
Ocugen
MALVERN, Pa., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
13 déc. 2022 08h00 HE
|
Ocugen
MALVERN, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
07 déc. 2022 08h00 HE
|
Ocugen
Continued Positive Safety Data for OCU400 Established High Dose as the Maximum Tolerable Dose in Current OCU400 Clinical Trial MALVERN, Pa., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen...
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
28 nov. 2022 07h30 HE
|
Ocugen
MALVERN, Pa., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
08 nov. 2022 07h30 HE
|
Ocugen
Conference Call and Webcast Today at 8:30 a.m. ET Initiated dosing in the third and final cohort of U.S. Phase 1/2 OCU400 gene therapy clinical trialExpanded product pipeline with OCU500—Ocugen’s...